Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ANPEP | P15144 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10364634 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1HPGDGAAANPEP | |
| SCHEMBL10964506 | 0.90 | KDM4E (0.70) | KDM4EALDH1A1HPGDGAAANPEP | |
| SCHEMBL10964500 | 0.90 | KDM4E (0.70) | KDM4EALDH1A1HPGDGAAANPEP | |
| Gamma-Aminobutyric Acid SCHEMBL10362615 | 0.89 | KDM4E (0.51) | KDM4EALDH1A1HPGDGAAANPEP | |
| SCHEMBL10362609 | 0.85 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDGAAKMT2A | |
| SCHEMBL10362607 | 0.85 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDGAAKMT2A | |
| SCHEMBL10363008 | 0.81 | KDM4E (0.57) | KDM4EALDH1A1HPGDGAAANPEP | |
| SCHEMBL10362881 | 0.81 | KDM4E (0.76) | KDM4EALDH1A1HPGDGAASMN1; SMN2 | |
| SCHEMBL10362896 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAASMN1; SMN2 | |
| SCHEMBL10362895 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| EP-0147211-B1 | 4H-3,1-BENZOXAZIN-4-ONES AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | SYNTEX (U.S.A.) INC. (US) | 1990-09-12 | — | — | EP | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | KDM4E 2361/4885ALDH1A1 1149/4885HPGD 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.